论文部分内容阅读
口服血小板糖蛋白Ⅱb/Ⅲa(GPⅡb/Ⅲa)受体拮抗剂能降低冠状动脉成形术的缺血并发症。口服GPⅡb/Ⅲa受体拮抗剂还能持续发挥受体拮抗作用,长期预防继发性损害,但其临床疗效尚不清楚。
Oral platelet glycoprotein Ⅱ b / Ⅲ a (GP Ⅱ b / Ⅲ a) receptor antagonist can reduce the ischemic complications of coronary angioplasty. Oral GP Ⅱ b / Ⅲ a receptor antagonists can also continue to play a role in receptor antagonism, long-term prevention of secondary damage, but its clinical efficacy is not yet clear.